Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chronic Liver Diseases Therapeutics Market Grown from 2024 to 2025?
The market size for therapeutics in chronic liver disease has witnessed a swift expansion in the past few years. Projected growth indicates that it will advance from $14.38 billion in 2024 to $15.92 billion in 2025, marking a compound annual growth rate (CAGR) of 10.7%. Factors contributing to past growth include the surging cases of viral hepatitis, an increase in obesity rates, an aging population, heightened awareness about liver health, and improved patient access to treatment.
What Growth Rate Is Anticipated for the Chronic Liver Diseases Therapeutics Market in the Coming Years?
In the coming years, the therapeutics market for chronic liver disease is predicted to grow swiftly, reaching $23.83 billion in 2029 with a compound annual growth rate (CAGR) of 10.6%. This forecasted growth is influenced by factors such as an increased emphasis on personalized medicine, a growing number of innovative therapies in the pipeline, the advancement of telemedicine and digital health solutions, and a rising demand for liver disease prevention initiatives. Additionally, a surge in viral hepatitis incidences has been noted. Major trends shaping the market include the incorporation of artificial intelligence into diagnostics, biologic and gene treatments, non-invasive treatment alternatives, combination therapies, and the development of patient-centric care models.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
Who Are the Leading Companies in the Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
What Are the Key Drivers of the Chronic Liver Diseases Therapeutics Market?
The rise in the consumption of alcohol is likely to drive the expansion of the chronic liver disease therapeutics market. The uptake of beverages containing ethanol, from moderate to high volumes, with potential health consequences, is termed as alcohol consumption. The upswing in alcohol intake can be attributed to its growing social acceptance, rising income levels, and increased availability worldwide. Therapeutics for chronic liver disease help control liver damage triggered by excessive alcohol intake, slowing down the ailment’s advancement and enhancing liver function. For instance, in June 2024, the First Citizens Bank, a US-based financial firm, reported a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023, relative to 2022. Moreover, Kirin Holdings Company Limited, a beverage company based in Japan, in a report published in December 2023, noted that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase compared to the preceding year. Hence, the escalating consumption of alcohol is fuelling the expansion of the chronic liver disease therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp
What Are the Key Market Segments in the Chronic Liver Diseases Therapeutics Industry?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine, Hepatitis B Vaccine, Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
What Are the Latest Trends in the Chronic Liver Diseases Therapeutics Market?
Leading firms in the chronic liver diseases therapeutics market are concentrating their efforts on innovating advanced solutions, including RNA therapies that target specific genetic and molecular structures, thereby providing more personalized and potent treatment methods. RNA therapies are cutting-edge medical solutions that utilize RNA molecules to manage gene expression or protein creation, with the intention of treating or averting illnesses by targeting particular genetic processes. For instance, Ochre Bio, a biotech company based in the UK, unveiled its trailblazing ‘Liver ICU’ research facility at BioLabs@NYULangone, a biopharma incubator located in New York City, in May 2022. This advanced space evaluates the efficacy of next-generation RNA therapeutics utilizing complete human livers maintained on perfusion devices. The establishment aims to speed up drug development schedules and enhance liver treatment studies’ accuracy by replicating human physiological settings, made possible by the use of discarded donor livers for research.
Access The Full Report Here:
What Are the Key Regional Markets in the Chronic Liver Diseases Therapeutics Industry?
North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21145
This Report Delivers Insight On:
1. How big is the chronic liver diseases therapeutics market, and how is it changing globally?
2. Who are the major companies in the chronic liver diseases therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the chronic liver diseases therapeutics market right now?
4. Which products or customer segments are growing the most in the chronic liver diseases therapeutics market?
5. What factors are helping or slowing down the growth of the chronic liver diseases therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model